Drug Topics magazine, a trade publication for clinical pharmacists, recently interviewed a trio of SPHP pharmacists for an article examining the allocation of supplies of the drug remdesivir. […]
WTEN News10 interviewed Philip Palmieri, M.D., chief of infectious disease at St. Peter’s Hospital, for its story on clinical trials involving the drug, remdesivir. […]
WTEN/News10 aired a story on multiple therapies being used to treat critically ill COVID-19 patients at St. Peter’s and Samaritan hospitals. […]
Jorge Cerda, M.D., chief of the Department of Medicine at St. Peter’s Hospital, was interviewed by WNYT about new treatments being offered to COVID-19 patients at St. Peter’s and Samaritan hospitals. This includes experimental convalescent plasma, and as well other antiviral and anti-inflammatory drug treatments. […]
The Times Union did a story about how SPHP is among the first hospital systems nationwide to receive federal approval for an experimental COVID-19 treatment. […]
Multiple groundbreaking therapies to treat the sickest COVID-positive patients in the Capital Region are being employed at St. Peter’s Health Partners’ (SPHP) acute care hospitals in Albany and Troy. They include the antiviral drug remdesivir; IL-6 inhibitor drugs; macrophage inhibitors; and convalescent blood plasma therapy. […]
© 2024 St. Peter's Health Partners. All rights reserved.
315 S. Manning Blvd., Albany, NY 12208, 518-525-1111